antibodies for the treatment of mds: magrolimab & sabatolimab
Published 2 years ago • 152 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:28
cd47 antibodies for the treatment of aml and mds: where is the field moving?
-
1:41
the role of antibody-based therapies in mds treatment
-
1:18
the mechanism of action of anti-cd47 antibodies & where these may fit in the mds treatment landscape
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
0:51
phase ii trial of ag-946 in patients with low-risk mds and anemia
-
2:43
novel therapies in the future of mds treatment
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
4:54
imugene reports promising results in phase 1b trial for azer-cel in dlbcl
-
4:48
managing and treating mds
-
3:49
cd47 discovery: flipping the script on cancer | stanford cancer institute
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
2:36
safety and preliminary efficacy of elotuzumab and belantamab mafodotin in patients with r/r myeloma
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
1:12
the safety and efficacy of mb-106 for the treatment of waldenström’s macroglobulinemia
-
1:41
an overview of the mds diagnosis pathway
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
2:09
an overview of the management of patients with r/r waldenström’s macroglobulinemia
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all